Agelink M W, Lemmer W, Malessa R, Zeit T, Majewski T, Klieser E
Department of Psychiatry, Evangelical Hospital Gelsenkirchen, University of Bochum, Germany.
Alcohol Alcohol. 1998 Nov-Dec;33(6):602-5. doi: 10.1093/alcalc/33.6.602.
Standardized investigations on resting heart rate variability (HRV) should provide more information on acamprosate's human pharmacodynamic properties because acamprosate interacts with several neurotransmitter systems which are also involved in maintaining autonomic neurocardiac balance. We performed HRV measurements prospectively in 69 healthy controls and 19 chronic alcoholics to prove the hypotheses that: (1) compared to healthy controls, chronic alcoholics show disturbances in neurocardiac vagal function; and (2) in alcoholics, acamprosate treatment (6-8 days) should further decrease parasympathetic activity if acamprosate interacts with central gamma-aminobutyric acidA receptors in vivo. Cardiovagal dysfunction was initially present in 21% of the alcoholics. After treatment. however, their neurocardiac sympathetic-parasympathetic balance improved significantly.
对静息心率变异性（HRV）进行标准化研究应能提供更多有关阿坎酸人体药效学特性的信息，因为阿坎酸与多个神经递质系统相互作用，而这些神经递质系统也参与维持自主神经心脏平衡。我们对69名健康对照者和19名慢性酒精中毒者进行了前瞻性HRV测量，以验证以下假设：（1）与健康对照者相比，慢性酒精中毒者表现出神经心脏迷走神经功能紊乱；（2）在酒精中毒者中，如果阿坎酸在体内与中枢γ-氨基丁酸A受体相互作用，阿坎酸治疗（6 - 8天）应会进一步降低副交感神经活动。21%的酒精中毒者最初存在心血管迷走神经功能障碍。然而，治疗后，他们的神经心脏交感 - 副交感神经平衡显著改善。
